Global Rna Interference (Rnai) Drug Delivery Market Forecast 2024-2032

Global Rna Interference (Rnai) Drug Delivery Market Forecast 2024-2032

The global RNA interference (RNAi) drug delivery market size was $66,442.85 million in 2023 and is expected to reach $406,320.39 million by 2032, growing at a CAGR of 22.24% during the forecast period. The base year considered for the study is 2023, and the estimated period is between 2024 and 2032.

The RNAi technology has emerged as a promising therapeutic approach, harnessing the body's natural mechanism of gene silencing. RNAi drugs, also known as small interfering RNAs (siRNAs), can selectively target and degrade specific disease-causing genes, offering potential treatments for various conditions. However, delivering these therapeutic molecules presents a critical challenge due to their susceptibility to degradation and the barriers they encounter in reaching their target cells and tissues.

Consequently, to overcome these obstacles, researchers have developed various drug delivery systems for RNA therapeutics, including lipid nanoparticles, polymer-based nanocarriers, and conjugation with targeting ligands. These systems are designed to shield siRNAs from degradation, aid in their uptake by cells, and improve their specificity for targeting desired cells or tissues.

A substantial challenge in RNAi therapy is the potential for RNAi off-target effects, where the siRNAs unintentionally silence genes other than the intended target. This can lead to undesirable side effects and reduced therapeutic efficacy. In this regard, researchers are continuously working on improving the specificity and potency of RNAi therapeutics through advanced RNA interference drug delivery technology and chemical modifications.

Furthermore, RNA interference (RNAi) is a natural cellular process that selectively degrades specific messenger RNAs (mRNAs), regulating gene expression and preventing the production of corresponding proteins. RNAi delivery methods aim to use this mechanism for therapeutic purposes by introducing synthetic siRNAs into target cells or tissues. Several RNAi companies, including Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Dicerna Pharmaceuticals, are actively involved in developing and commercializing RNAi therapeutics. As the field of RNAi drug delivery continues to evolve, collaboration between academia, industry, and regulatory agencies will be crucial. This collaboration is necessary for addressing the remaining challenges and translating this promising technology into safe and effective treatments for patients.

MARKET INSIGHTS

Key growth enablers of the global RNA interference (RNAi) drug delivery market:

• Increasing demand for RNA-based therapeutics to stimulate market growth

• Rising prevalence of chronic diseases fosters market demand

o The increasing prevalence of chronic diseases can be attributed to factors such as an aging population and the rise in lifestyle diseases. This trend underscores the growing demand for innovative treatments, including those leveraging RNA interference technology.

o According to WHO statistics, the proportion of the world’s population over 60 years old is projected to almost double from 12% to 22% by 2050. This shift is a result of longer life expectancies and declining birth rates in various regions globally.

o Additionally, it is a trend that underscores the importance of healthcare innovation, including advancements in RNA therapeutics, to meet the needs of an aging society.

• Growing investment in RNA-based research to escalate the market growth

Key growth restraining factors of the global RNA interference (RNAi) drug delivery market:

• The complexity of RNAi technology is predicted to hinder market demand

• Regulatory challenges are expected to further complicate market growth

o The regulatory landscape for RNAi therapeutics presents considerable challenges due to the novelty and complexity of this technology. Regulatory agencies, such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established rigorous standards and requirements for developing and approving RNAi-based therapies.

Global RNA Interference (RNAi) Drug Delivery Market | Top Market Trends

• RNAi drugs have reflected effectiveness in cancer treatment by targeting genes involved in tumorigenesis, leading to antiproliferative and proapoptotic effects. However, challenges persist in drug delivery and toxicity. Despite these challenges, the substantial annual investments of over $50 billion in cancer research highlight the potential of RNAi therapies to address unmet needs in oncology.

• The success of mRNA vaccines during the COVID-19 pandemic has heightened awareness and acceptance of RNA-based therapeutics. This has underlined the potential of RNAi drugs in treating zoonotic and other infectious diseases, with climate change and increased human-animal interactions raising the likelihood of future pandemics.

• Venture capital and corporate funding for RNAi drugs have experienced a surge, propelled by their potential to transform the pharmaceutical industry.

SEGMENTATION ANALYSIS

Market Segmentation – Application and Technology –

Market by Application:

• Oncology

o In 2023, the oncology segment was the largest application category in the global RNA interference (RNAi) drug delivery market.

o RNAi has shown immense potential in the field of oncology. These drugs can target oncogenes, anti-apoptotic genes, and genes involved in angiogenesis by silencing specific genes associated with tumor growth, metastasis, and resistance to traditional therapies.

• Infectious Disease

• Neurology

• Cardiology

• Metabolic Disorders

• Ophthalmology

• Urology

• Other Applications

Market by Technology:

• Nanoparticle Drug Delivery

• Pulmonary Drug Delivery

• Nucleic Acid Drug Delivery

• Aptamer Drug Delivery

REGIONAL ANALYSIS

Geographical Study based on Four Major Regions:

• North America: The United States and Canada

o In 2023, North America was the major region in the global RNA interference (RNAi) drug delivery market.

o North America, particularly the United States, is a global leader in biotechnology research and development.

o Numerous pharmaceutical and biotech companies, along with academic institutions, are actively engaged in RNAi research, contributing to the development of novel RNAi-based therapies for various therapeutic areas.

• Europe: The United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe

• Asia-Pacific: China, Japan, India, South Korea, Australia & New Zealand, Thailand, Indonesia, Vietnam, and Rest of Asia-Pacific

• Rest of World: Latin America, the Middle East & Africa

COMPETITIVE INSIGHTS

Major players in the global RNA interference (RNAi) drug delivery market:

• Alnylam Pharmaceuticals Inc

• Arbutus Biopharma Corporation

• Arcturus Therapeutics Inc

• Arrowhead Pharmaceuticals Inc

• Benitec Biopharma Inc

• Genevant Sciences Corporation

• Ionis Pharmaceuticals Inc

• OliX Pharmaceuticals

• Silence Therapeutics PLC

• Sirnaomics Inc

Key strategies adopted by some of these companies:

• Benitec Biopharma reported positive interim clinical trial data for the first OPMD subject treated with BB-301 in a Phase 1b/2a study in April 2024.

• Arcturus Therapeutics and the Cystic Fibrosis Foundation extended their agreement in September 2023 to advance ARCT-032, an investigational mRNA therapeutic for treating cystic fibrosis.

• Alnylam announced a partnership with Roche in July 2023 to co-develop and co-commercialize Zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension in patients with high cardiovascular risk.

We Offer 10% Free Customization and 3 Months Analyst Support

Frequently Asked Questions (FAQs):

• What is the estimated market revenue value of the global RNA interference (RNAi) drug delivery market?

A: The global RNA interference (RNAi) drug delivery market is anticipated to generate a revenue of $406,320.39 million in 2032.

• Which RNA interference (RNAi) drug delivery application comprises the major market share?

A: In 2023, the oncology application comprised the major market share and is projected to retain the position in 2032.

• Which RNA interference (RNAi) drug delivery technology is anticipated to grow at a faster rate?

A: Pulmonary drug delivery technology is anticipated to grow at a faster rate during the forecast period.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.